We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Pipeline

Project : MMB101

Indication : Immuno-Oncology

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I

MMB101 is a humanized anti-TIGIT monoclonal antibody designed to target a novel epitope
spanning multiple PVR binding sites for optimized functional coverage.

Learn more
Project : MMB102

Indication : Immuno-Oncology

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I

MMB102 is a GITR agonistic antibody designed to achieve an anti-cancer immune response via deactivation of immuno-suppressive Treg cells and activation of CD8+ effector T cells.

Learn more
Project : MFA011

Indication : Immuno-Oncology

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I

MFA011 is a fusion antibody with MediMabBio’s proprietary anti-TIGIT antibody and IL15 cytokines.

Learn more
Project : MFA021

Indication : Immuno-Oncology

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I
Project : MMB301

Indication : Immuno-Oncology

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I
Product Indication Therapeutic Modality Target Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I Link
Oncology
MMB101 Immuno-Oncology Monoclonal Antibody anti-TIGIT Learn more
MMB102 Immuno-Oncology Monoclonal Antibody anti-GITR Learn more
MFA011 Immuno-Oncology Fusion Antibody anti-TIGIT & IL15R Learn more
MFA021 Immuno-Oncology Fusion Antibody anti-GITR & IL15R
Inflammatory Disease
MFA031 Autoimmune Disease Neutralizing Antibody Undisclosed